Posizioni attive di Bernard Pau
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Phost’in SAS
 Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France. | Presidente | 17/06/2020 | - |
| Direttore operativo | 17/06/2020 | - |
Storia della carriera di Bernard Pau
Precedenti posizioni note di Bernard Pau
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Biodol Therapeutics SAS
 Biodol Therapeutics SAS BiotechnologyHealth Technology Biodol Therapeutics SAS engages in the development of compounds for the treatment of chronic pain. It specializes in parallel small-molecule FLT3 inhibitors. The company was founded by Fabien Granier, Pierre Sokoloff and Bernard Pau in 2015 and is headquartered in Clapiers, France. | Fondatore | 01/01/2015 | - |
Statistiche
Distribuzione geografica
| Francia | 3 |
Posizioni
| Chairman | 1 |
| Chief Operating Officer | 1 |
| Founder | 1 |
Settori
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Phost’in SAS
Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France. | Health Technology |
Biodol Therapeutics SAS
Biodol Therapeutics SAS BiotechnologyHealth Technology Biodol Therapeutics SAS engages in the development of compounds for the treatment of chronic pain. It specializes in parallel small-molecule FLT3 inhibitors. The company was founded by Fabien Granier, Pierre Sokoloff and Bernard Pau in 2015 and is headquartered in Clapiers, France. | Health Technology |
- Borsa valori
- Insiders
- Bernard Pau
- Esperienza
